Concepedia

Xiaotian Zhu

XZ

Statistics

Publications

32

Citations

5.3K

H-Index

25

Active since

1995

Affiliations

Ariadne Diagnostics (United States)(Current)

Howard Hughes Medical Institute

Dana-Farber Cancer Institute

University of Science and Technology of China

Brigham and Women's Hospital

Xiaotian Zhu is an author at Ariadne Diagnostics (United States) specializing in pharmacology, tyrosine kinase inhibitors, and medicine.

ORCID

Publications per year

1995–2022

32

Publications

32

Structural Analysis of Substrate Binding by the Molecular Chaperone DnaK

Xiaotian Zhu, Xun Zhao, William F. Burkholder et al. · Science · 1996 · 1.3K citations

, , +17

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

, , +9

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

, , +13

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 362 citations · Full text

, , +12

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 326 citations · Full text

, , +15

1–5 of 32